Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2023-08-22 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
半年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 95% confidence The document is a summary table detailing non-operating fund occupation and other related party fund transactions for the period January to June 2023. It includes financial figures and relationships between the listed company and related parties. The document is relatively short (1391 characters) and appears to be a regulatory disclosure of related party transactions rather than a full financial report. It does not contain comprehensive financial statements or management discussion. It is not an announcement of a report publication but a specific regulatory disclosure. Given the nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2023-08-22 Chinese
2023年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "江苏四环生物股份有限公司2023 年半年度报告全文" which translates to "Jiangsu Sihuan Bioengineering Co., Ltd. 2023 Semi-Annual Report Full Text." It contains detailed financial data, management discussion and analysis, company business overview, risk factors, governance information, environmental and social responsibility, and financial statements. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. The content includes actual financial figures, analysis, and comprehensive reporting for a half-year period, which matches the definition of an Interim / Quarterly Report (IR). There is no indication that this is merely an announcement or a certification, and it is not a full annual report (10-K) but a half-year report. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2023
2023-08-22 Chinese
2023年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "江苏四环生物股份有限公司2023 年半年度财务报告" which translates to "Jiangsu Sihuan Biological Co., Ltd. 2023 Semi-Annual Financial Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity for the half-year period ending June 30, 2023. The report explicitly states it is a half-year (semi-annual) financial report and includes comprehensive financial data and analysis for this period. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is an announcement or a certification document. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-22 Chinese
江苏四环生物股份有限公司关于重大诉讼事项的进展公告
Legal Proceedings Report Classification · 95% confidence The document is an announcement from Jiangsu Sihuan Bio Co., Ltd. regarding the progress of a significant litigation matter. It details the background of the lawsuit, the first-instance civil judgment, and the potential impact on the company. The document does not contain financial statements or detailed financial analysis but focuses on legal proceedings and updates related to a court case. Therefore, it fits the category of Legal Proceedings Report (LTR). The document length is short and it is not a report publication announcement or certification. Hence, the classification is LTR with high confidence.
2023-08-02 Chinese
江苏四环生物股份有限公司关于实际控制人部分股份解除司法冻结、轮候冻结及司法标记的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Jiangsu Sihuan Bio Co., Ltd. regarding the partial release of judicial freeze, queued freeze, and judicial marks on shares held by the actual controller. It details the number of shares affected, dates of freezing and release, and confirms that these changes do not affect control or company operations. The document is short (1758 characters) and focuses on legal and regulatory disclosure about share status changes, not financial results or management reports. It does not contain financial statements or detailed analysis. This type of announcement fits best under Regulatory Filings (RNS), as it is a regulatory disclosure about share status and legal restrictions, not a financial report or voting result.
2023-07-26 Chinese
江苏四环生物股份有限公司关于实际控制人部分股份被冻结、轮候冻结及司法标记的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Jiangsu Sihuan Biological Co., Ltd. regarding the freezing, judicial marking, and pledge status of shares held by the actual controller and related parties. It details the number of shares frozen, the reasons (contract disputes), and the legal entities involved. The document does not contain financial statements, management discussion, or earnings data. It is a regulatory announcement about share status and legal actions affecting shareholding, not a financial report or management report. The document length is under 5,000 characters and is a formal disclosure of share freezing and judicial marks, fitting the category of Regulatory Filings (RNS) as it is a compliance disclosure about share status and legal matters.
2023-07-25 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.